Hugel Aesthetics Showcases Growing U.S. Presence, Clinical Innovation and K-Aesthetic Leadership at 2026 ASDS Annual Meeting
Company highlights Letybo®, presents clinic research and engages with industry leaders through scientific data, brand activations and executive events
Irvine, Calif., Nov. 18, 2026
Hugel Aesthetics, a global leader in medical aesthetics, reinforced its expanding U.S. footprint at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting. Held Nov. 5–8 in San Diego, the meeting brought together leading physicians, researchers and industry stakeholders shaping the future of aesthetic medicine.
As a partner of the ASDS Industry Advisory Council (IAC), Hugel collaborates with the organization to support research and advancement in dermatologic surgery. Throughout the meeting, Hugel’s commercial, medical affairs and executive leadership teams engaged with industry leaders through strategic stakeholder discussions, podcast interviews and a company-hosted reception.

The company’s presence at the meeting reflects its broader commitment to advancing evidence-based innovation and expanding awareness of K-Aesthetics among U.S. providers and patients. Beyond the convention floor, Hugel further amplified its visibility through on-site scientific data presentations highlighting clinical evidence supporting Letybo (letibotulinumtoxinA-wlbg) and a branded mobile activation showcasing Letybo and K-Aesthetics.
“ASDS brings together some of the most influential voices in dermatology and aesthetics, making it an important forum for scientific collaboration and innovation,” said Carrie Strom, CEO of Hugel Aesthetics. “As we continue to expand our presence in the United States, we are proud to partner with the ASDS so that we can contribute meaningful clinical research that helps providers make informed treatment decisions and deliver positive patient outcomes.”
Clinical Data Featured at ASDS
Analyses from the BLESS clinical program, authored by board-certified dermatologist and dermatologic surgeon Michael H. Gold, MD, further reinforced the efficacy behind Letybo, speed of onset and patient satisfaction.
Results from the Phase 3 Bless III study1 showed that 64.7% of patients treated with Letybo achieved the study’s primary measure for improvement at four weeks, compared with 0% receiving placebo. Patients experienced a median time to improvement of three days, and no serious treatment-related adverse events were reported.
Among women ages 35 to 50, post hoc analyses2 demonstrated rapid and sustained results, with up to 87.4% achieving improvement by week two and 73.6% showing no visible frown lines at maximum frown (GLS 0 on the Glabellar Line Scale) by week four.
A pooled analysis3 of 1,272 participants across three BLESS trials also demonstrated meaningful improvements in quality of life, emotional well-being and treatment satisfaction compared to placebo.
The findings contribute to the growing body of evidence supporting Letybo and underscore Hugel Aesthetics’ commitment to advancing research that informs patient care and provider decision making.
About Hugel Aesthetics
Established in 2001, Hugel is a global leader in medical aesthetics, specializing in the production of injectables for skin rejuvenation, including botulinum toxin, hyaluronic acid fillers, and skin boosters, as well as absorbable sutures and cosmetic products. With a proven track record of safety and quality, Hugel is deeply committed to advancing the industry through robust medical affairs, comprehensive training programs and dynamic industry forums.
Over the past 25 years, the company has built a presence in more than 70 countries and operates 11 global subsidiaries across the U.S., Australia, Canada, Taiwan, China, Hong Kong, Singapore and Thailand. Leveraging strong industry momentum, Hugel is well-positioned for continued growth and market expansion worldwide.
References
- Michael H. Gold, MD, “Efficacy and Safety of LetibotulinumtoxinA in the Treatment of Glabellar Lines: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study,” Abstract Featured at the 2026 American Society for Dermatologic Surgery Annual Meeting
- Michael H. Gold, MD, “Efficacy and Safety of LetibotulinumtoxinA in the Treatment of Moderate and Severe Glabellar Lines in Females Aged 35-50 Years: BLESS III Post Hoc Analyses,” Abstract Featured at the 2026 American Society for Dermatologic Surgery Annual Meeting
- Michael H. Gold, MD, “Reduced Psychosocial Burden and High Patient Satisfaction Associated With Glabellar Lines Treatment With LetibotulinumtoxinA: BLESS Phase 3 Trials,” Abstract Featured at the 2026 American Society for Dermatologic Surgery Annual Meeting